Literature DB >> 32779107

The use of glycosylated hemoglobin (HbA1c) as a predictor of the severity of acute coronary syndrome among diabetic patients.

Ahmed Abdalazim Dafallah Albashir1, Omer Ali Mohamed Ahmed Elawad2, Hussam Khougali Mohamed2.   

Abstract

BACKGROUND: Acute myocardial infarction in patients with type two diabetes mellitus is usually present with multiple vessel lesions during coronary angiography. The underlying mechanism remains unexplored, and there is a deficiency of serum predictive markers. Glycosylated hemoglobin (HbA1c), which is a critical measure of glycemic control, could be used as a reliable predictor of the severity of ACS.
MATERIALS AND METHODS: This is a prospective descriptive comparative hospital-based study measured the correlation between levels of HbA1c and the severity of ACS using the modified Gensini score (MGS). A total of 85 patients were enrolled in this study in the period between September and November 2019. The MGS depends on the number of vessels which are stenosed with the degree of stenosis more than 50% of their lumen. Data was analyzed using SPSS V. 2018. Chi-square test was used.
RESULTS: The total number of enrolled patients was 85. Dyslipidemia was found among 63 (74.1%) patients, and 52 (69.4%) of the patients were noted to have hypertension. A total of 19 (22.4%) patients were smokers. About 59 (69.4%) patients had a family history of IHD, and 22 patients (25.9%) had a history of IHD. STEMI was the main ECG finding 54 (63.5%). Modified Gensini score depicted that 32 (35.29%) had mild acute coronary syndrome, 23(27.06%) had moderate, and 30 (37.65%) had severe acute coronary syndrome. HbA1c was significantly positively correlated with the severity of ACS among diabetic patients (P value = 0.000).
CONCLUSION: In diabetic patients with acute coronary syndrome, HbA1c levels can be used as a predictor for the severity of CAD.

Entities:  

Keywords:  Acute coronary syndrome; Diabetes mellitus; HbA1c

Mesh:

Substances:

Year:  2020        PMID: 32779107     DOI: 10.1007/s11845-020-02341-0

Source DB:  PubMed          Journal:  Ir J Med Sci        ISSN: 0021-1265            Impact factor:   1.568


  5 in total

Review 1.  Diabetes and cardiovascular disease: Epidemiology, biological mechanisms, treatment recommendations and future research.

Authors:  Benjamin M Leon; Thomas M Maddox
Journal:  World J Diabetes       Date:  2015-10-10

2.  Prevalence of diabetic foot ulceration and associated risk factors: an old and still major public health problem in Khartoum, Sudan?

Authors:  Ahmed O Almobarak; Heitham Awadalla; Mugtaba Osman; Mohamed H Ahmed
Journal:  Ann Transl Med       Date:  2017-09

Review 3.  Acute myocardial infarction in sub-Saharan Africa: the need for data.

Authors:  Julian T Hertz; Joseph M Reardon; Clarissa G Rodrigues; Luciano de Andrade; Alexander T Limkakeng; Gerald S Bloomfield; Catherine A Lynch
Journal:  PLoS One       Date:  2014-05-09       Impact factor: 3.240

4.  Correlation between Gensini Score and Duration of Diabetes in Patients Undergoing Coronary Angiography.

Authors:  Razi Ul Amin; Muhammad Anis M Ahmedani; Musa Karim; Ahmed Raheem
Journal:  Cureus       Date:  2019-02-04

5.  Prevalence and Risk Factors for Acute Coronary Syndrome Among Sudanese Individuals With Diabetes: A Population-Based Study.

Authors:  Mohamed H Ahmed; Heitham Awadalla; Wadie M Elmadhoun; Mugtaba Osman; Sufian K Noor; Ahmed O Almobarak
Journal:  Cardiol Res       Date:  2017-10-27
  5 in total
  2 in total

1.  Evaluation of salusin-α and salusin-β levels in patients with type 2 diabetes mellitus and determination of the impact of severity of hyperglycemia on salusin levels.

Authors:  Derya Argun; Ferit Argun; Betul Borku Uysal
Journal:  Ir J Med Sci       Date:  2021-06-09       Impact factor: 1.568

2.  Hemoglobin A1c level is a prognostic factor for locoregional recurrence in stage III non-small cell lung cancer patients treated with radiotherapy.

Authors:  Moonkyoo Kong; Yu Jin Lim
Journal:  Thorac Cancer       Date:  2021-10-01       Impact factor: 3.500

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.